Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GST037
MIFTS: 59

Gastroparesis

Categories: Gastrointestinal diseases, Metabolic diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastroparesis

About this section

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 53 29 55 44 15 73
Delayed Gastric Emptying 53
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
Anatomical: Gastrointestinal diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:11914
ICD10 33 K31.84
ICD9CM 35 536.3
MeSH 44 D018589
NCIt 50 C80512
SNOMED-CT 68 77164002
UMLS 73 C0152020
Sources

Summaries for Gastroparesis

About this section
NIH Rare Diseases : 53 Gastroparesis, or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine. In gastroparesis,  the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers, gastroesophageal reflux, esophagitis, small bowel bacterial overgrowth, and metabolic bone disease.  In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery.  Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma, autoimmune conditions, neuromuscular diseases, psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test. Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator, and medication such as metoclopramide, domperidone, erythromycin and cisapride.  With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to stomach disease and dyspepsia, and has symptoms including hemiplegia, ophthalmoplegia and lassitude. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Domperidone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, small intestine and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Gastroparesis (GP also called delayed gastric emptying) is a medical condition consisting of a paresis... more...

Sources

Related Diseases for Gastroparesis

About this section

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 stomach disease 31.6 GAST GHRL MLN
2 dyspepsia 30.2 CCK GHRL HTR3A
3 pylorospasm 29.9 GAST GHRL MLN
4 gastroesophageal reflux 29.7 CCK GAST GHRL MLN
5 duodenogastric reflux 29.6 CCK GAST MLN
6 parkinson disease, late-onset 29.6 CYP2D6 DRD2 HMOX1 NOS1
7 constipation 29.4 CCK GAST HTR3A MLN MLNR
8 peptic ulcer disease 29.4 GAST GHRL
9 bulimia nervosa 29.4 CCK GHRL HTR3A
10 irritable bowel syndrome 29.3 CCK HTR3A MLN
11 diarrhea 29.3 ABCB1 CCK GAST HTR3A
12 brittle diabetes 11.1
13 diabetes mellitus 10.4
14 helicobacter pylori infection 10.3
15 galactorrhea 10.2 CYP2D6 DRD2
16 codeine toxicity 10.2 ABCB1 CYP2D6
17 delusional disorder 10.2 CYP2D6 DRD2
18 anorexia nervosa 10.2
19 tardive dyskinesia 10.2 CYP2D6 DRD2
20 functional colonic disease 10.2 MLN MLNR
21 atrial fibrillation 10.2
22 neuropathy 10.2
23 colonic pseudo-obstruction 10.1 MLN MLNR
24 neuroleptic malignant syndrome 10.1 CYP2D6 DRD2
25 blind loop syndrome 10.1 GHRL MLN
26 paralytic ileus 10.1 ABCB1 CCK
27 opioid abuse 10.1 CCK DRD2
28 non-functioning pancreatic endocrine tumor 10.1 GAST GHRL
29 autoimmune disease of gastrointestinal tract 10.0 CYP2D6 GAST
30 small cell cancer of the lung 10.0
31 achalasia 10.0
32 nasal cavity adenocarcinoma 10.0 CCK GAST
33 celiac disease 1 10.0
34 gastritis 10.0
35 pneumonia 10.0
36 pancreatic cholera 10.0 CCK GAST
37 duodenal gastrinoma 10.0 CCK GAST
38 opioid addiction 10.0 ABCB1 CCK DRD2
39 postcholecystectomy syndrome 10.0 CCK GAST MLN
40 multiple sclerosis 10.0
41 lung cancer 10.0
42 cystic fibrosis 10.0
43 pancreatic cancer 10.0
44 demyelinating disease 10.0
45 pancreatitis 10.0
46 dysphagia 10.0
47 renovascular hypertension 10.0 HMOX1 NOS1
48 space motion sickness 10.0 CCK GAST MLN
49 disease of mental health 10.0 CCK CYP2D6 DRD2
50 pancreatic steatorrhea 10.0 CCK GHRL

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis
Sources

Symptoms & Phenotypes for Gastroparesis

About this section

UMLS symptoms related to Gastroparesis:


hemiplegia, ophthalmoplegia, lassitude, persistent vomiting, signs and symptoms, digestive

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.32 GHSR HTR3A MLN
2 Decreased viability GR00381-A-2 9.32 GHSR
3 Decreased viability GR00381-A-3 9.32 GHSR HTR3A MLN
4 Decreased viability GR00402-S-2 9.32 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 ABCB1 CCK DRD2 GHRL GHSR HMOX1
2 endocrine/exocrine gland MP:0005379 9.86 ABCB1 CCK DRD2 GAST GHRL HMOX1
3 homeostasis/metabolism MP:0005376 9.81 ABCB1 CCK DRD2 GAST GHRL GHSR
4 adipose tissue MP:0005375 9.8 DRD2 GHRL GHSR HMOX1 NOS1
5 digestive/alimentary MP:0005381 9.8 ABCB1 DRD2 GAST GHRL GHSR NOS1
6 no phenotypic analysis MP:0003012 9.35 ABCB1 CCK DRD2 GHSR NOS1
7 renal/urinary system MP:0005367 9.02 CCK DRD2 HMOX1 HTR3A NOS1
Sources

Drugs & Therapeutics for Gastroparesis

About this section

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57808-66-9 3151
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
3
Ticagrelor Approved Phase 4 274693-27-5 9871419
4
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
5
Esomeprazole Approved, Investigational Phase 4,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
6
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754
7
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2 50-03-3
8
Pasireotide Approved Phase 4 396091-73-9 9941444
9
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53608-75-6
10
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
11
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
12
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
13
Carbidopa Approved Phase 4 28860-95-9 34359 38101
14
Levodopa Approved Phase 4,Phase 2,Not Applicable 59-92-7 6047
15
Tadalafil Approved, Investigational Phase 4,Phase 2 171596-29-5 110635
16
Thrombin Approved, Investigational Phase 4
17
Haloperidol Approved Phase 4 52-86-8 3559
18
Exenatide Approved, Investigational Phase 4,Phase 1,Phase 2 141758-74-9 15991534
19
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
20 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
21 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Chelating Agents Phase 4,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
27 Citrate Phase 4,Not Applicable
28 Anticoagulants Phase 4,Not Applicable
29 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Calcium, Dietary Phase 4,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Analgesics, Non-Narcotic Phase 4
34 Analgesics Phase 4,Phase 2
35 Antipyretics Phase 4
36 glucagon Phase 4
37 Glucagon-Like Peptide 1 Phase 4
38 Anti-Ulcer Agents Phase 4,Phase 1,Not Applicable
39 Antacids Phase 4,Phase 1,Not Applicable
40 Proton Pump Inhibitors Phase 4,Not Applicable
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
42 Cortisol succinate Phase 4,Phase 2
43 Hormone Antagonists Phase 4,Phase 2,Phase 1
44 Hormones Phase 4,Phase 1,Phase 2
45 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2
46 Hydrocortisone-17-butyrate Phase 4,Phase 2
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Coagulants Phase 4,Not Applicable
49 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Fibrin Tissue Adhesive Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
3 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
4 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
5 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
6 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Unknown status NCT02775227 Phase 4 Hydrocortisone;Pasireotide
7 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
8 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
9 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
10 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
11 An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
12 An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
13 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
14 Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis Terminated NCT00390975 Phase 4 Tegaserod
15 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
16 An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects Terminated NCT02793154 Phase 4 Exenatide;Albiglutide
17 Gastric vs Jejunal Feeding in Diabetic Gastroparesis Withdrawn NCT00944593 Phase 4
18 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
19 Sancuso® for Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
20 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
21 A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction Unknown status NCT01460550 Phase 3
22 Nortriptyline for Idiopathic Gastroparesis Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
23 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
24 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
25 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
26 Prucalopride Versus Placebo in Gastroparesis Completed NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
27 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Completed NCT01149369 Phase 3 Aprepitant;Placebo
28 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility Completed NCT01379183 Phase 2, Phase 3 Erythromycin;Placebo
29 Standardization of Surgery on the Pancreatic Cancer Completed NCT00679913 Phase 3
30 Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy Completed NCT01544790 Phase 3
31 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 Recruiting NCT03383146 Phase 3 Relamorelin;Placebo
32 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Recruiting NCT03285308 Phase 3 Relamorelin;Placebo
33 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02 Recruiting NCT03426345 Phase 3 Relamorelin;Placebo
34 Domperidone in Treating Patients With Gastrointestinal Disorders Recruiting NCT01696734 Phase 3 Domperidone
35 REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY) Recruiting NCT03030170 Phase 3
36 Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy Recruiting NCT03398291 Phase 3 Standard chemotherapy
37 Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve Recruiting NCT02524626 Phase 3
38 Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Active, not recruiting NCT02457156 Phase 3 Octreotide
39 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Enrolling by invitation NCT03420781 Phase 3 Relamorelin;Placebo
40 PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial) Enrolling by invitation NCT03331718 Phase 3 PGA felt reinforcement
41 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Not yet recruiting NCT02927886 Phase 3
42 Diabetic Gastroparesis Study 05 Not yet recruiting NCT03786380 Phase 3 Relamorelin 10 μg
43 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
44 Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy Not yet recruiting NCT03419676 Phase 3
45 Acupuncture for Diabetic Gastroparesis Suspended NCT00470795 Phase 3
46 Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus Terminated NCT00228891 Phase 2, Phase 3
47 The Use of Domperidone for Gastroparesis Withdrawn NCT01378884 Phase 3 Domperidone
48 Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
49 Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes Withdrawn NCT00228904 Phase 2, Phase 3
50 Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People Unknown status NCT02308254 Phase 1, Phase 2 Lixisenatide;Placebo

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: gastroparesis

Sources

Genetic Tests for Gastroparesis

About this section

Genetic tests related to Gastroparesis:

# Genetic test Affiliating Genes
1 Gastroparesis 29
Sources

Anatomical Context for Gastroparesis

About this section

MalaCards organs/tissues related to Gastroparesis:

41
Testes, Small Intestine, Bone, Lung, Liver, Colon, Pancreas
Sources

Publications for Gastroparesis

About this section

Articles related to Gastroparesis:

(show top 50) (show all 1481)
# Title Authors Year
1
Epidemiology and Pathophysiology of Gastroparesis. ( 30396519 )
2019
2
Stent Placement for the Treatment of Gastroparesis. ( 30396520 )
2019
3
Diabetic Gastroparesis and Nondiabetic Gastroparesis. ( 30396524 )
2019
4
Clinical Manifestation and Natural History of Gastroparesis. ( 30396526 )
2019
5
Evaluation of Patients with Suspected Gastroparesis. ( 30396527 )
2019
6
Symptomatic Management of Gastroparesis. ( 30396528 )
2019
7
Gastric Electrical Stimulator for Treatment of Gastroparesis. ( 30396529 )
2019
8
Surgical Management for Gastroparesis. ( 30396530 )
2019
9
Botulinum Toxin Injection for Treatment of Gastroparesis. ( 30396531 )
2019
10
Gastroparesis: New Approaches in Management. ( 30396532 )
2019
11
Gastroparesis: Current Opinions and New Endoscopic Therapies. ( 30396533 )
2019
12
Helping Patients with Gastroparesis. ( 30466677 )
2019
13
Glycosylated hemoglobin level may predict the severity of gastroparesis in diabetic patients. ( 29111279 )
2018
14
G-POEM for Gastroparesis: Is There Pressure to Go with the Flow? ( 29855769 )
2018
15
Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. ( 29808246 )
2018
16
The effect of extracorporeal low-energy shockwave on diabetic gastroparesis in a rat model. ( 29966170 )
2018
17
Pyloric sphincter characteristics using EndoFLIP<sup>Ar</sup> in gastroparesis. ( 29709494 )
2018
18
Delivery of Mesenchymal Stem Cells from Gelatin-Alginate Hydrogels to Stomach Lumen for Treatment of Gastroparesis. ( 29414870 )
2018
19
A Critical Review of the Current Clinical Landscape of Gastroparesis. ( 29928159 )
2018
20
LncRNA MALAT1 is up-regulated in diabetic gastroparesis and involved in high-glucose-induced cellular processes in human gastric smooth muscle cells. ( 29317209 )
2018
21
Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. ( 29111115 )
2018
22
Therapeutic response to domperidone in gastroparesis: AA prospective study using the GCSI-daily diary. ( 29110425 )
2018
23
The Challenges of Gastroparesis: Changing Study Design to Improve Clinical Care. ( 29875453 )
2018
24
Gastric per-oral endoscopic myotomy for refractory gastroparesis: a detailed description of the procedure, our experience, and review of the literature. ( 29435752 )
2018
25
Gastroparesis following resection of a fourth ventricle ependymoma in a child. ( 29933085 )
2018
26
Diabetic Gastroparesis: Principles and Current Trends in Management. ( 29934758 )
2018
27
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation. ( 29795419 )
2018
28
Post-pancreatitis diabetes mellitus and gastroparesis: driven together? ( 29914234 )
2018
29
Characterizing Abdominal Pain in Patients With Gastroparesis Into Neuropathic and Nociceptive Components. ( 29782470 )
2018
30
Intravenous immunoglobulin in drug and device refractory patients with the symptoms of gastroparesis-an open-label study. ( 29205691 )
2018
31
Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. ( 29895073 )
2018
32
Endoscopic Therapies for Gastroparesis. ( 29687294 )
2018
33
Gastric Peroral Endoscopic Pyloromyotomy Reduces Symptoms, Increases Quality of Life, and Reduces Health Care Use For Patients With Gastroparesis. ( 29660525 )
2018
34
Challenges in defining, diagnosing, and treating diabetic gastroparesis. ( 29198995 )
2018
35
The Investigation and Treatment of Diabetic Gastroparesis. ( 29748143 )
2018
36
State of the art review with literature summary on gastric peroral endoscopic pyloromyotomy for gastroparesis. ( 29806114 )
2018
37
Glass half empty? Lessons learned about gastroparesis. ( 29862014 )
2018
38
Efficacy of needleless transcutaneous electroacupuncture in synchronization with breathing for symptomatic idiopathic gastroparesis: A blinded and controlled acute treatment trial. ( 29745434 )
2018
39
A longitudinal study on patients with diabetes and symptoms of gastroparesis - associations with impaired quality of life and increased depressive and anxiety symptoms. ( 29153755 )
2018
40
Peroral endoscopic myotomy and peroral endoscopic pyloromyotomy as a single procedure for concomitant achalasia and gastroparesis. ( 30231260 )
2018
41
Gastroparesis in a Patient with Gastric AL Amyloidosis. ( 30022922 )
2018
42
Ficus carica aqueous extract alleviates delayed gastric emptying and recovers ulcerative colitis-enhanced acute functional gastrointestinal disorders in rats. ( 29870788 )
2018
43
New developments in the treatment of gastroparesis and functional dyspepsia. ( 30245474 )
2018
44
Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment. ( 30509017 )
2018
45
Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. ( 28970332 )
2018
46
Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. ( 29052298 )
2018
47
Exploring Symptom Severity, Illness Perceptions, Coping Styles, and Well-Being in Gastroparesis Patients Using the Common Sense Model. ( 29468373 )
2018
48
Gastric Per Oral Endoscopic Myotomy (G-POEM) for the Treatment of Refractory Gastroparesis: Early Experience. ( 29468376 )
2018
49
Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with Diabetes and Symptoms of Gastroparesis. ( 29487566 )
2018
50
Role of Laparoscopic-Assisted Gastric Per-oral Endoscopic Pyloromyotomy in Refractory Gastroparesis. ( 29502199 )
2018
Sources

Variations for Gastroparesis

About this section
Sources

Expression for Gastroparesis

About this section
Search GEO for disease gene expression data for Gastroparesis.
Sources

Pathways for Gastroparesis

About this section

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 12.9 CCK DRD2 GHRL GHSR MLN MLNR
2
cAMP signaling pathway 37
Show member pathways
 11.74 DRD2 GHRL GHSR
3
Doxorubicin Pathway, Pharmacokinetics 61
Show member pathways
 10.97 ABCB1 NOS1
4
Codeine and Morphine Pathway, Pharmacokinetics 61
Show member pathways
 10.9 ABCB1 CYP2D6
5
Ondansetron Pathway, Pharmacokinetics/Pharmacodynamics 61
Show member pathways
 10.13 CYP2D6 HTR3A
6
Gastric acid production 1
9.47 CCK GAST
Sources

GO Terms for Gastroparesis

About this section

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.26 CCK DRD2 GHRL HTR3A
2 glutamatergic synapse GO:0098978 8.92 DRD2 GHRL GHSR HTR3A

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.92 CCK GAST GHRL MLN
2 response to hypoxia GO:0001666 9.82 DRD2 HMOX1 NOS1
3 excitatory postsynaptic potential GO:0060079 9.71 DRD2 GHRL HTR3A
4 response to hormone GO:0009725 9.69 GHRL GHSR NOS1
5 response to cocaine GO:0042220 9.67 DRD2 HTR3A
6 response to nicotine GO:0035094 9.66 DRD2 HMOX1
7 negative regulation of blood pressure GO:0045776 9.65 DRD2 NOS1
8 positive regulation of sprouting angiogenesis GO:1903672 9.65 GHRL GHSR
9 exogenous drug catabolic process GO:0042738 9.64 CYP2D6 NOS1
10 decidualization GO:0046697 9.64 GHRL GHSR
11 positive regulation of vascular endothelial cell proliferation GO:1905564 9.63 GHRL GHSR
12 response to food GO:0032094 9.63 GAST GHSR
13 regulation of postsynapse organization GO:0099175 9.62 GHRL GHSR
14 regulation of sodium ion transport GO:0002028 9.61 DRD2 NOS1
15 actin polymerization or depolymerization GO:0008154 9.61 GHRL GHSR
16 positive regulation of growth GO:0045927 9.6 GHRL GHSR
17 adult feeding behavior GO:0008343 9.59 GHRL GHSR
18 negative regulation of interleukin-1 beta production GO:0032691 9.58 GHRL GHSR
19 negative regulation of appetite GO:0032099 9.58 CCK GHSR
20 positive regulation of growth hormone secretion GO:0060124 9.57 DRD2 GHRL
21 negative regulation of tumor necrosis factor secretion GO:1904468 9.56 GHRL GHSR
22 growth hormone secretion GO:0030252 9.55 GHRL GHSR
23 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.52 GHRL GHSR
24 positive regulation of multicellular organism growth GO:0040018 9.5 DRD2 GHRL GHSR
25 G protein-coupled receptor signaling pathway GO:0007186 9.5 CCK DRD2 GAST GHRL GHSR MLN
26 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.49 GHRL GHSR
27 positive regulation of appetite GO:0032100 9.48 GHRL GHSR
28 positive regulation of eating behavior GO:1904000 9.46 GHRL GHSR
29 regulation of transmission of nerve impulse GO:0051969 9.43 GHRL GHSR
30 positive regulation of small intestine smooth muscle contraction GO:1904349 9.4 GHRL GHSR
31 regulation of gastric motility GO:1905333 9.37 GHRL GHSR
32 negative regulation of insulin secretion GO:0046676 9.33 DRD2 GHRL GHSR
33 positive regulation of small intestinal transit GO:0120058 9.26 GHRL GHSR
34 postsynaptic modulation of chemical synaptic transmission GO:0099170 8.8 DRD2 GHRL GHSR
35 signal transduction GO:0007165 10.14 CCK DRD2 GAST GHSR HTR3A MLNR

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.33 CYP2D6 HMOX1 NOS1
2 hormone binding GO:0042562 8.96 GHSR MLNR
3 hormone activity GO:0005179 8.92 CCK GAST GHRL MLN
Sources

Sources for Gastroparesis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....